Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:age |
patients aged 4 to 17 years
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
V01AA11
|
| gptkbp:brand |
gptkb:Palforzia
|
| gptkbp:contains |
defatted peanut flour
|
| gptkbp:form |
powder
|
| gptkbp:hasBoxedWarning |
anaphylaxis
|
| https://www.w3.org/2000/01/rdf-schema#label |
peanut allergen powder-dnfp
|
| gptkbp:indication |
mitigation of allergic reactions to peanuts
|
| gptkbp:initialDoseEscalation |
0.5 mg
|
| gptkbp:maintenanceDose |
300 mg
|
| gptkbp:manufacturer |
gptkb:Aimmune_Therapeutics
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:riskFactor |
anaphylaxis
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:treatment |
oral immunotherapy
|
| gptkbp:usedFor |
peanut allergy
|
| gptkbp:bfsParent |
gptkb:Palforzia
|
| gptkbp:bfsLayer |
8
|